188 related articles for article (PubMed ID: 29541535)
1. Early fine motor impairment and behavioral dysfunction in (Thy-1)-h[A30P] alpha-synuclein mice.
Ekmark-Lewén S; Lindström V; Gumucio A; Ihse E; Behere A; Kahle PJ; Nordström E; Eriksson M; Erlandsson A; Bergström J; Ingelsson M
Brain Behav; 2018 Mar; 8(3):e00915. PubMed ID: 29541535
[TBL] [Abstract][Full Text] [Related]
2. Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.
Rabl R; Breitschaedel C; Flunkert S; Duller S; Amschl D; Neddens J; Niederkofler V; Rockenstein E; Masliah E; Roemer H; Hutter-Paier B
BMC Neurosci; 2017 Jan; 18(1):22. PubMed ID: 28143405
[TBL] [Abstract][Full Text] [Related]
3. Visualization of early oligomeric α-synuclein pathology and its impact on the dopaminergic system in the (Thy-1)-h[A30P]α-syn transgenic mouse model.
Behere A; Thörnqvist PO; Winberg S; Ingelsson M; Bergström J; Ekmark-Lewén S
J Neurosci Res; 2021 Oct; 99(10):2525-2539. PubMed ID: 34292621
[TBL] [Abstract][Full Text] [Related]
4. Behavioural and dopaminergic changes in double mutated human A30P*A53T alpha-synuclein transgenic mouse model of Parkinson´s disease.
Kilpeläinen T; Julku UH; Svarcbahs R; Myöhänen TT
Sci Rep; 2019 Nov; 9(1):17382. PubMed ID: 31758049
[TBL] [Abstract][Full Text] [Related]
5. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice.
Gomez-Isla T; Irizarry MC; Mariash A; Cheung B; Soto O; Schrump S; Sondel J; Kotilinek L; Day J; Schwarzschild MA; Cha JH; Newell K; Miller DW; Uéda K; Young AB; Hyman BT; Ashe KH
Neurobiol Aging; 2003; 24(2):245-58. PubMed ID: 12498958
[TBL] [Abstract][Full Text] [Related]
6. Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial induction.
Gentzel RC; Toolan D; Jinn S; Schachter JB; Ma L; Kahle PJ; Smith SM; Marcus JN
Neurobiol Aging; 2021 Oct; 106():12-25. PubMed ID: 34225000
[TBL] [Abstract][Full Text] [Related]
7. Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease.
Paumier KL; Sukoff Rizzo SJ; Berger Z; Chen Y; Gonzales C; Kaftan E; Li L; Lotarski S; Monaghan M; Shen W; Stolyar P; Vasilyev D; Zaleska M; D Hirst W; Dunlop J
PLoS One; 2013; 8(8):e70274. PubMed ID: 23936403
[TBL] [Abstract][Full Text] [Related]
8. Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse.
Taylor TN; Potgieter D; Anwar S; Senior SL; Janezic S; Threlfell S; Ryan B; Parkkinen L; Deltheil T; Cioroch M; Livieratos A; Oliver PL; Jennings KA; Davies KE; Ansorge O; Bannerman DM; Cragg SJ; Wade-Martins R
Neurobiol Dis; 2014 Feb; 62():193-207. PubMed ID: 24121116
[TBL] [Abstract][Full Text] [Related]
9. Mice Expressing A53T/A30P Mutant Alpha-Synuclein in Dopamine Neurons Do Not Display Behavioral Deficits.
Keomanivong C; Schamp J; Tabakovic E; Thangavel R; Aldridge G; Pieper AA; Narayanan NS
eNeuro; 2024 Feb; 11(2):. PubMed ID: 38351057
[TBL] [Abstract][Full Text] [Related]
10. Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.
Zhou W; Milder JB; Freed CR
J Biol Chem; 2008 Apr; 283(15):9863-70. PubMed ID: 18238775
[TBL] [Abstract][Full Text] [Related]
11. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
12. Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice.
Marxreiter F; Ettle B; May VE; Esmer H; Patrick C; Kragh CL; Klucken J; Winner B; Riess O; Winkler J; Masliah E; Nuber S
Neurobiol Dis; 2013 Nov; 59():38-51. PubMed ID: 23867236
[TBL] [Abstract][Full Text] [Related]
13. Age-related increase of alpha-synuclein oligomers is associated with motor disturbances in L61 transgenic mice.
Roshanbin S; Aniszewska A; Gumucio A; Masliah E; Erlandsson A; Bergström J; Ingelsson M; Ekmark-Lewén S
Neurobiol Aging; 2021 May; 101():207-220. PubMed ID: 33639338
[TBL] [Abstract][Full Text] [Related]
14. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
[TBL] [Abstract][Full Text] [Related]
15. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
[TBL] [Abstract][Full Text] [Related]
16. A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein.
Richter F; Subramaniam SR; Magen I; Lee P; Hayes J; Attar A; Zhu C; Franich NR; Bove N; De La Rosa K; Kwong J; Klärner FG; Schrader T; Chesselet MF; Bitan G
Neurotherapeutics; 2017 Oct; 14(4):1107-1119. PubMed ID: 28585223
[TBL] [Abstract][Full Text] [Related]
17. Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α-synuclein inclusions.
Stoyka LE; Arrant AE; Thrasher DR; Russell DL; Freire J; Mahoney CL; Narayanan A; Dib AG; Standaert DG; Volpicelli-Daley LA
Neurobiol Dis; 2020 Feb; 134():104708. PubMed ID: 31837424
[TBL] [Abstract][Full Text] [Related]
18. Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.
Maki RA; Holzer M; Motamedchaboki K; Malle E; Masliah E; Marsche G; Reynolds WF
Free Radic Biol Med; 2019 Sep; 141():115-140. PubMed ID: 31175983
[TBL] [Abstract][Full Text] [Related]
19. A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.
Wrasidlo W; Tsigelny IF; Price DL; Dutta G; Rockenstein E; Schwarz TC; Ledolter K; Bonhaus D; Paulino A; Eleuteri S; Skjevik ÅA; Kouznetsova VL; Spencer B; Desplats P; Gonzalez-Ruelas T; Trejo-Morales M; Overk CR; Winter S; Zhu C; Chesselet MF; Meier D; Moessler H; Konrat R; Masliah E
Brain; 2016 Dec; 139(Pt 12):3217-3236. PubMed ID: 27679481
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice.
Lindström V; Fagerqvist T; Nordström E; Eriksson F; Lord A; Tucker S; Andersson J; Johannesson M; Schell H; Kahle PJ; Möller C; Gellerfors P; Bergström J; Lannfelt L; Ingelsson M
Neurobiol Dis; 2014 Sep; 69():134-43. PubMed ID: 24851801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
